VIR
insider transactionsVir Biotechnology, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 90d
-219.4K
0 buy · 219.4K sell
Net value · 90d
-$2.8M
$0 in · $2.8M out
Sentiment · 90d
Net selling
0% buying · 100% selling
Open-market trades · 90d
9
0 buy · 219.4K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Exercise·M
Director · 10b5-1
$0
10.0K sh
Own New
-
Sell·S
Director · 10b5-1
$500.7K
10.0K sh · $50.07
Own -15%
-
Exercise·M
Director · 10b5-1
$265.2K
10.0K sh · $26.52
Own +18%
-
Grant·A
Director
$0
16.0K sh
Own New
-
Grant·A
Director
$0
8.0K sh
Own New
-
Sell·S
SVP, Chief Accounting Officer · 10b5-1
$3.6K
379 sh · $9.45
Own -1%
-
Sell·S
Director · 10b5-1
$30.2K
3.2K sh · $9.45
Own -13%
-
Grant·A
Director
$0
16.0K sh
Own New
-
Grant·A
Director
$0
8.0K sh
Own +25%
-
Grant·A
Director
$0
16.0K sh
Own New
-
Grant·A
Director
$0
8.0K sh
Own +49%
-
Grant·A
Director
$0
16.0K sh
Own New
-
Grant·A
Director
$0
8.0K sh
Own +25%
-
Grant·A
Director
$0
16.0K sh
Own New
-
Grant·A
Director
$0
8.0K sh
Own +33%
-
Grant·A
Director
$0
16.0K sh
Own New
-
Grant·A
Director
$0
8.0K sh
Own +60%
-
Grant·A
Director
$0
12.0K sh
Own New
-
Grant·A
Director
$0
4.0K sh
Own +8%
-
Sell·S
Director · 10b5-1
$141.3K
3.2K sh · $43.49
Own -6%
-
Grant·A
Director
$0
50.0K sh
Own New
-
Sell·S
Director · 10b5-1
$221.0K
22.0K sh · $10.05
Own -2%
-
Other·J
President and CEO
$0
233.5K sh
-
Exercise·M
Ramy Farid KEY
President & CEO · 10b5-1
$0
74.5K sh
Own New
-
Exercise·M
Ramy Farid KEY
President & CEO · 10b5-1
$0
43.0K sh
Own +136%
-
Exercise·M
Ramy Farid KEY
President & CEO · 10b5-1
$228.8K
74.5K sh · $3.07
Own +23%
-
Sell·S
Ramy Farid KEY
President & CEO · 10b5-1
$524.9K
43.0K sh · $12.21
Own -12%
-
Exercise·M
Ramy Farid KEY
President & CEO · 10b5-1
$132.0K
43.0K sh · $3.07
Own +13%
-
Exercise·M
Ramy Farid KEY
President & CEO · 10b5-1
$0
43.0K sh
Own +58%
-
Sell·S
Ramy Farid KEY
President & CEO · 10b5-1
$530.2K
43.0K sh · $12.33
Own -12%
-
Exercise·M
Ramy Farid KEY
President & CEO · 10b5-1
$132.0K
43.0K sh · $3.07
Own +13%
-
Sell·S
President and CEO · 10b5-1
$664.4K
72.6K sh · $9.16
Own -7%
-
Sell·S
Director · 10b5-1
$199.6K
22.0K sh · $9.07
Own -2%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 12, 2026 | Timothy Coughlin 10b5-1 | Exercise M | 10.0K | $0 |
| Jun 12, 2026 | Timothy Coughlin 10b5-1 | Sell S | 10.0K | $500.7K |
| Jun 12, 2026 | Timothy Coughlin 10b5-1 | Exercise M | 10.0K | $265.2K |
| Jun 9, 2026 | Timothy Coughlin | Grant A | 16.0K | $0 |
| Jun 9, 2026 | Timothy Coughlin | Grant A | 8.0K | $0 |
| Jun 1, 2026 | Brent Sabatini 10b5-1 | Sell S | 379 | $3.6K |
| Jun 1, 2026 | Janet Napolitano 10b5-1 | Sell S | 3.2K | $30.2K |
| May 27, 2026 | Charles Elliott Sigal | Grant A | 16.0K | $0 |
| May 27, 2026 | Charles Elliott Sigal | Grant A | 8.0K | $0 |
| May 27, 2026 | Janet Napolitano | Grant A | 16.0K | $0 |
| May 27, 2026 | Janet Napolitano | Grant A | 8.0K | $0 |
| May 27, 2026 | Jeffrey S. Hatfield | Grant A | 16.0K | $0 |
| May 27, 2026 | Jeffrey S. Hatfield | Grant A | 8.0K | $0 |
| May 27, 2026 | Ramy Farid | Grant A | 16.0K | $0 |
| May 27, 2026 | Ramy Farid | Grant A | 8.0K | $0 |
| May 27, 2026 | Norbert W Bischofberger | Grant A | 16.0K | $0 |
| May 27, 2026 | Norbert W Bischofberger | Grant A | 8.0K | $0 |
| May 19, 2026 | Timothy Coughlin | Grant A | 12.0K | $0 |
| May 19, 2026 | Timothy Coughlin | Grant A | 4.0K | $0 |
| May 15, 2026 | Timothy Coughlin 10b5-1 | Sell S | 3.2K | $141.3K |
| May 11, 2026 | Timothy Coughlin | Grant A | 50.0K | $0 |
| May 1, 2026 | Vicki L Sato 10b5-1 | Sell S | 22.0K | $221.0K |
| Apr 29, 2026 | Marianne De Backer KEY | Other J | 233.5K | $0 |
| Apr 17, 2026 | Ramy Farid KEY 10b5-1 | Exercise M | 74.5K | $0 |
| Apr 17, 2026 | Ramy Farid KEY 10b5-1 | Exercise M | 43.0K | $0 |
| Apr 17, 2026 | Ramy Farid KEY 10b5-1 | Exercise M | 74.5K | $228.8K |
| Apr 17, 2026 | Ramy Farid KEY 10b5-1 | Sell S | 43.0K | $524.9K |
| Apr 17, 2026 | Ramy Farid KEY 10b5-1 | Exercise M | 43.0K | $132.0K |
| Apr 16, 2026 | Ramy Farid KEY 10b5-1 | Exercise M | 43.0K | $0 |
| Apr 16, 2026 | Ramy Farid KEY 10b5-1 | Sell S | 43.0K | $530.2K |
| Apr 16, 2026 | Ramy Farid KEY 10b5-1 | Exercise M | 43.0K | $132.0K |
| Apr 6, 2026 | Marianne De Backer KEY 10b5-1 | Sell S | 72.6K | $664.4K |
| Apr 1, 2026 | Vicki L Sato 10b5-1 | Sell S | 22.0K | $199.6K |
About VIR insider trading
This page tracks insider transactions for Vir Biotechnology, Inc. (VIR) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.